SHIJIAZHUANG CITY, China
Lianhua Qingwen Capsules, a Chinese traditional medicine produced by Yiling Pharmaceutical, has been approved by the Food and Drug Administration of the Philippines and become a Chinese medicine product officially recognized in the Philippines. Approved by the China National Medical Products Administration, Lianhua Qingwen Capsules is a Chinese traditional medicine that can treat lightly and ordinarily infected patients by novel coronavirus. The Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 1 to 8), jointly-published by the China National Health Commission and National Administration of Traditional Chinese Medicine, has suggested Lianhua Qingwen Capsules to be used during the medical observation period of novel coronavirus patients.
Up to now, Lianhua Qingwen Capsules has obtained approval certificates from nearly 20 countries, including the Philippines, and Yiling has been applying it for approval in more than 70 countries. The approval of Lianhua Qingwen in the Philippines is a win-win case: on one hand, there is an urgent need of medicine in the Philippines that can effectively treat the novel coronavirus, the market potential is huge, Lianhua Qingwen’s entry into the Philippine market is an important step of Yiling’s internationalization path; on the other hand, as a Chinese enterprise that would like to shoulder global responsibility, Yiling is willing to share its experience in the fight against the pandemic with the world, the ultimate beneficiary of Lianhua Qingwen’s approval in the Philippines will be the Philippine people.
China is holding great expectations to the performances of Lianhua Qingwen Capsules in the Philippines. The Chinese Embassy to the Philippines has issued a specific statement to congratulate the approval, and pointed out that the Philippine consumers better purchase and use the qualified products imported through legal channels, they are expecting Lianhua Qingwen to help the Philippine government and people fight the novel coronavirus pneumonia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201206005002/en/
CONTACT
First Name: Li
Last Name: Kristy
E-mail:kristyli@chuhaimedia.com.cn
Phone No.: +86 85962566
